Three Brothers Trading, LLC v. Generex Biotechnology Corp.

CourtDistrict Court, S.D. New York
DecidedApril 24, 2020
Docket1:18-cv-11585
StatusUnknown

This text of Three Brothers Trading, LLC v. Generex Biotechnology Corp. (Three Brothers Trading, LLC v. Generex Biotechnology Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Three Brothers Trading, LLC v. Generex Biotechnology Corp., (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK THREE BROTHERS TRADING, LLC, Petitioner, 18 Civ. 11585 (KPF) -v.- OPINION AND ORDER GENEREX BIOTECHNOLOGY CORP., Respondent. KATHERINE POLK FAILLA, District Judge: As a wise man once remarked, it’s like déjà vu all over again. Less than two years ago, Three Brothers Trading, LLC d/b/a Alternative Execution Group (“AEXG” or “Petitioner”) and Generex Biotechnology Corporation (“Generex” or “Respondent”) participated in an arbitration proceeding, after which the arbitrator (the “Arbitrator”) issued an award in favor of AEXG (the “Award”). AEXG and Generex filed cross-petitions under the Federal Arbitration Act (the “FAA”), 9 U.S.C. §§ 1-14, asking this Court to confirm the Award and to vacate, modify, or remand the Award for clarification, respectively. In an Opinion issued on July 31, 2019, the Court remanded the Award to the Arbitrator for clarification. See Three Brothers Trading, LLC v. Generex Biotechnology Corp., No. 18 Civ. 11585 (KPF), 2019 WL 3456631, at *4 (S.D.N.Y. July 31, 2019) (“AEXG I”). On August 28, 2019, the Arbitrator issued his clarification. In response, AEXG filed an amended petition, asking the Court to confirm in part and vacate in part the Award. Generex filed a cross-petition, seeking to have the Award vacated and/or modified. The parties then filed cross-motions for summary judgment reiterating these requests for relief. For the reasons set forth below, AEXG’s motion to confirm in part and vacate in part is granted, and Generex’s cross-motion is denied. BACKGROUND1

A. Factual Background 1. The Parties’ Contract, Dispute, Arbitration, and Award For the sake of completeness, the Court first reviews the factual background that led to AEXG I, before discussing what has transpired since that decision was issued. This case arose from Generex’s alleged breach of a Memorandum of Understanding with AEXG (the “Contract”) entered into in February 2017. (Resp. 56.1 ¶ 7). In brief, the Contract provided that AEXG

1 The facts stated herein are drawn from Petitioner’s Local Rule 56.1 Statement of Material Facts Not in Dispute (“Pet. 56.1” (Dkt. #54)), and Respondent’s Statement of Material Facts Pursuant to Local Civil Rule 56.1 (“Resp. 56.1” (Dkt. #57)), the latter of which comprises both responses to Petitioner’s assertions of material facts not in dispute and material facts ostensibly in dispute. The Opinion also draws from the final arbitration award issued on December 3, 2018 (the “Award” (Dkt. #1-1)), and from the clarification of the Award issued on August 28, 2019 (the “Clarification” (Dkt. #30-1)). For ease of reference, AEXG’s Amended Petition is referred to as “Am. Pet.” (Dkt. #36); Generex’s Amended Cross-Petition as “Am. Cross-Pet.” (Dkt. #45); AEXG’s Memorandum of Law in Support of Its Second Motion for Summary Judgment as “Pet. Br.” (Dkt. #50); Generex’s Memorandum of Law in Opposition to AEXG’s Second Motion for Summary Judgment and in Support of Its Second Motion for Summary Judgment as “Resp. Br.” (Dkt. #58); AEXG’s Memorandum of Law in in Opposition to Generex’s Second Motion for Summary Judgment and in Further Support of Its Second Motion for Summary Judgment as “Pet. Reply;” (Dkt. #63); and Generex’s Memorandum of Law in Further Support of Its Second Motion for Summary Judgment as “Resp. Reply” (Dkt. #66). Citations to the parties’ Rule 56.1 Statements incorporate by reference the documents and deposition testimony cited therein. See Local Rule 56.1(d). Generally speaking, where facts stated in a party’s Local Rule 56.1 Statement are supported by testimonial or documentary evidence, and denied with only a conclusory statement by the other party, the Court finds such facts to be true. See Local Rule 56.1(c), (d); Biberaj v. Pritchard Indus., Inc., 859 F. Supp. 2d 549, 553 n.3 (S.D.N.Y. 2012) (“A nonmoving party’s failure to respond to a Rule 56.1 statement permits the court to conclude that the facts asserted in the statement are uncontested and admissible.” (internal quotation mark omitted) (quoting T.Y. v. N.Y.C. Dep’t of Educ., 584 F.3d 412, 418 (2d Cir. 2009))). would secure investors for Generex’s business and, in exchange, Generex would pay AEXG a percentage of the funds received by any investor AEXG had referred. (Id. at ¶¶ 8-9).

The Contract included a “sixty-day ‘No Shop’ exclusivity provision” (the “No Shop Provision”), which barred Generex from entering “into any financing transaction other than with existing shareholders” or with investors referred by AEXG. (Resp. 56.1 ¶¶ 14-15). The exclusivity period ran from February 8, 2017, to April 9, 2017. (Id.). If Generex breached the No Shop Provision, the Contract obligated Generex “to compensate [AEXG] as if [AEXG] had sourced the financing” itself. (Id. at ¶¶ 17-18). In that instance, Generex was required to pay AEXG damages, to include warrants for Generex stock in an amount

“determined based on the amount of financing [Generex] received.” (Id. at ¶¶ 17-21). The Contract also required the parties to resolve any disputes through arbitration. (Id. at ¶¶ 23, 24). In March 2017, Generex allegedly breached the Contract by entering into a financial transaction with a party not referred to them by AEXG. (Resp. 56.1 ¶¶ 30-33). In consequence, on November 27, 2017, AEXG sent a Demand for Arbitration Letter to Generex, demanding that the parties submit their dispute to arbitration before the American Arbitration Association (the “AAA”). (Id. at

¶ 36). In the demand, AEXG requested “$210,000, along with 84,000 warrants convertible to Generex common stock, exercisable at $2.50 per share, plus accrued simple interest running at New York’s statutory rate of 9% from March 28, 2017, along with attorneys’ fees, costs, and expenses. (Id. at ¶ 37). The AAA’s International Centre for Dispute Resolution managed the arbitration proceedings, and the parties agreed that arbitrator Daniel F. Kolb would preside over the case. (Id. at ¶¶ 39-40). An arbitration hearing was held on

September 24, 2018 (the “Hearing”). (Id. at ¶ 47). A few weeks after the Hearing, Generex announced that the company would issue a stock dividend (the “Dividend”). (Resp. 56.1 ¶ 52). The Dividend would result in the issuance of twenty shares of common stock for every one share of either issued or outstanding common stock. (Id.). The announcement included a statement explaining that any “options, warrants, and convertible securities” would be “proportionally adjusted to reflect the dividend.” (Id. at ¶¶ 53-54). Generex did not include a price floor that options, warrants, or

convertible securities had to be “at or above” in order to “receive the benefit of the proportional adjustment” of the Dividend. (Id. at ¶ 55). On November 14, 2018, Generex announced that the “record date to participate in the Stock Dividend was extended to November 20, 2018 and the dividend payment date was set for Friday, November 30, 2018.” (Resp. 56.1 ¶¶ 59, 60). The stock market reflected the Dividend for the first time on December 3, 2018. (Id. at ¶ 79). Since the announcement of the Dividend occurred after September 24,

2018, the parties were unable to introduce arguments at the Hearing concerning how the Dividend might impact the value of stock warrants owed to AEXG. (Resp. 56.1 ¶ 62). Instead, on November 2, 2018, AEXG submitted a letter to the Arbitrator that included Generex’s announcements about the Dividend. (Id. at ¶¶ 63-64, 66). AEXG requested that the Arbitrator take the Dividend into account when determining the amount of warrants to issue in the Award. (Id.). It reasoned that had Generex not breached the Contract,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Rich v. Spartis
516 F.3d 75 (Second Circuit, 2008)
Jock v. Sterling Jewelers Inc.
646 F.3d 113 (Second Circuit, 2011)
Florasynth, Inc. v. Alfred Pickholz
750 F.2d 171 (Second Circuit, 1984)
William H. Hyle, Jr. v. Doctor's Associates, Inc.
198 F.3d 368 (Second Circuit, 1999)
Reliastar Life Insurance v. EMC National Life Co.
564 F.3d 81 (Second Circuit, 2009)
Zeiler v. Deitsch
500 F.3d 157 (Second Circuit, 2007)
Clarendon National Insurance v. TIG Reinsurance Co.
990 F. Supp. 304 (S.D. New York, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
Three Brothers Trading, LLC v. Generex Biotechnology Corp., Counsel Stack Legal Research, https://law.counselstack.com/opinion/three-brothers-trading-llc-v-generex-biotechnology-corp-nysd-2020.